A compound having the following formula I:
1
where R
1
is alkyl group or alkenyl group, X represents
2
R
2
is selected from the group consisting of a halogen (o, m, p) group such as F, Cl, Br or I, —NH
2
, —NO
2
and a hydrogen group, R
3
is a hydrogen group or OH, and n is 0 to 2. The compound has pharmacologically &agr;
2
-adrenergic/5-HT
2A
antagonist activity, 5-HT re-uptake activity, and anti-oxidant activity. The compound is produced by preparing 4-epoxy isoeugenol, mixing piperazine dissolved in methanol with the 4-epoxy isoeugenol to reflux at 100° C. for approximately 2 to approximately 6 hours, removing the methanol, passing the mixture through a silica gel column chromatography after the removing step, eluting the passed mixture with n-hexane and ethyl acetate, drying the eluted mixture, and crystallizing the dried mixture with methanol.
具有以下
化学式I的化合物:其中R1是烷基或烯基基团,X代表R2从卤素(o,m,p)基团(如F、Cl、Br或I)、—NH2、—
NO2和氢基团中选择,R3是氢基团或OH,n为0至2。该化合物具有药理学α2-
肾上腺素/5-HT2A拮抗活性、5-HT再摄取活性和抗氧化活性。该化合物通过制备4-环氧异丁基
酚,将
丙二胺溶解在
甲醇中与4-环氧异丁基
酚混合,在100°C回流约2至约6小时,去除
甲醇,经过去除步骤后通过
硅胶柱色谱法将混合物通过,用
正己烷和
乙酸乙酯洗脱通过的混合物,干燥洗脱的混合物,并用
甲醇结晶干燥的混合物。